コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ve therapy group (antiretroviral therapy and isoniazid preventive therapy).
2 CWs to be offered antiretroviral therapy and isoniazid preventive therapy.
3 r-randomized, phased-implementation trial of isoniazid preventive therapy.
4 in 7 years of follow-up for those initiating isoniazid preventive therapy.
5 tment; if not, they were offered 9 months of isoniazid preventive therapy.
6 afe initiation of antiretroviral therapy and isoniazid preventive therapy.
7 uld have greater confidence in the safety of isoniazid preventive therapy.
8 or this purpose in assessing indications for isoniazid preventive therapy.
9 July 1992 and January 1994 and were offered isoniazid preventive therapy.
10 e test, 409 (50%) fit current guidelines for isoniazid preventive therapy, 84 (20%) we intended to tr
11 (95% CI 3.5-7.8) for empirical group and for isoniazid preventive therapy (95% CI 3.4-7.8); absolute
12 with HIV infection in Botswana receive daily isoniazid preventive therapy against tuberculosis withou
13 an help to prioritize active case finding or isoniazid preventive therapy among children exposed to T
14 f infected individuals who were eligible for isoniazid preventive therapy and the poor adherence with
15 6% received a medical examination, 91% began isoniazid preventive therapy, and 82% completed preventi
17 It is likely that antiretroviral therapy and isoniazid preventive therapy can be started safely in pe
18 nostics, reducing treatment delay, providing isoniazid preventive therapy continuously to human immun
20 creening, active disease treatment, and mass isoniazid preventive therapy for 9 months during 2006-20
21 gramme scenario, a combination of continuous isoniazid preventive therapy for individuals on antiretr
23 cident cases of tuberculosis; 37 were in the isoniazid preventive therapy group (2.3 per 100 person-y
24 y and empirical tuberculosis therapy) or the isoniazid preventive therapy group (antiretroviral thera
25 ncentrations in 19 of 662 individuals in the isoniazid preventive therapy group and ten of the 667 in
29 t would reduce early mortality compared with isoniazid preventive therapy in high-burden settings.
30 rculosis (MTB) infection and indications for isoniazid preventive therapy in HIV-infected persons.
31 omparing empirical tuberculosis therapy with isoniazid preventive therapy in HIV-positive outpatients
32 t reduce mortality at 24 weeks compared with isoniazid preventive therapy in outpatient adults with a
33 ion of systematic tuberculosis screening and isoniazid preventive therapy in outpatients with advance
34 med a phase I randomized controlled trial of isoniazid preventive therapy (IPT) before revaccination
35 The World Health Organization recommends isoniazid preventive therapy (IPT) for HIV-positive cont
38 young child contacts (<5 years) who received isoniazid preventive therapy (IPT) had developed disease
39 sified tuberculosis case finding or prior to isoniazid preventive therapy (IPT) in patients infected
40 es and produced a high rate of completion of isoniazid preventive therapy (IPT) in those persons afte
43 ive tuberculin skin tests (TST) benefit from isoniazid preventive therapy (IPT) whereas those testing
44 early antiretroviral therapy (ART), 6-month isoniazid preventive therapy (IPT), or both among HIV-in
46 protection against tuberculosis provided by isoniazid preventive therapy is not known for human immu
48 rticipants were randomly assigned to receive isoniazid preventive therapy (n=662) or placebo (n=667)
49 CI, 1.57 to 22.01; p = 0.009), self-reported isoniazid preventive therapy (odds ratio, 0.18; CI, 0.04
51 ly assigned (1:1) patients to receive either isoniazid preventive therapy or a placebo for 12 months
52 eligible pregnant women living with HIV for isoniazid preventive therapy or for further investigatio
53 d a community-based tuberculin screening and isoniazid preventive therapy project among high-risk inn
54 ultivariate algorithm that predicts benefit, isoniazid preventive therapy should be recommended to al
56 e if they had completed at least 5 months of isoniazid preventive therapy, unless they had completed
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。